These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 18501601

  • 1. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
    Lohar MV, Mundada R, Bhonde M, Padgaonkar A, Deore V, Yewalkar N, Bhatia D, Rathos M, Joshi K, Vishwakarma RA, Kumar S.
    Bioorg Med Chem Lett; 2008 Jun 15; 18(12):3603-6. PubMed ID: 18501601
    [Abstract] [Full Text] [Related]

  • 2. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.
    Sun HL, Liu YN, Huang YT, Pan SL, Huang DY, Guh JH, Lee FY, Kuo SC, Teng CM.
    Oncogene; 2007 Jun 07; 26(27):3941-51. PubMed ID: 17213816
    [Abstract] [Full Text] [Related]

  • 3. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 4. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
    Jin X, Jin HR, Lee D, Lee JH, Kim SK, Lee JJ.
    Eur J Pharmacol; 2008 Sep 11; 592(1-3):41-7. PubMed ID: 18639543
    [Abstract] [Full Text] [Related]

  • 5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 6. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
    Granville CA, Memmott RM, Gills JJ, Dennis PA.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):679-89. PubMed ID: 16467077
    [Abstract] [Full Text] [Related]

  • 7. Impact of cyclic hypoxia on HIF-1alpha regulation in endothelial cells--new insights for anti-tumor treatments.
    Martinive P, Defresne F, Quaghebeur E, Daneau G, Crokart N, Grégoire V, Gallez B, Dessy C, Feron O.
    FEBS J; 2009 Jan 01; 276(2):509-18. PubMed ID: 19077164
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway.
    Won MS, Im N, Park S, Boovanahalli SK, Jin Y, Jin X, Chung KS, Kang M, Lee K, Park SK, Kim HM, Kwon BM, Lee JJ, Lee K.
    Biochem Biophys Res Commun; 2009 Jul 17; 385(1):16-21. PubMed ID: 19433063
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
    Liang J, Ge F, Guo C, Luo G, Wang X, Han G, Zhang D, Wang J, Li K, Pan Y, Yao L, Yin Z, Guo X, Wu K, Ding J, Fan D.
    FEBS J; 2009 Feb 17; 276(3):685-94. PubMed ID: 19143835
    [Abstract] [Full Text] [Related]

  • 15. RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR.
    Liu Z, Yuan Q, Zhang X, Xiong C, Xue P, Ruan J.
    Cancer Chemother Pharmacol; 2012 Jun 17; 69(6):1633-40. PubMed ID: 22565593
    [Abstract] [Full Text] [Related]

  • 16. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
    Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, Yu Y, Zha X, Feng Y.
    Cell Res; 2008 Jul 17; 18(7):780-91. PubMed ID: 18574502
    [Abstract] [Full Text] [Related]

  • 17. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells.
    Choi UJ, Jee BK, Lim Y, Lee KH.
    Cell Biochem Funct; 2009 Jan 17; 27(1):40-7. PubMed ID: 19107873
    [Abstract] [Full Text] [Related]

  • 18. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
    Woodard J, Sassano A, Hay N, Platanias LC.
    Clin Cancer Res; 2008 Jul 15; 14(14):4640-9. PubMed ID: 18628479
    [Abstract] [Full Text] [Related]

  • 19. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P.
    Curr Opin Pharmacol; 2008 Aug 15; 8(4):393-412. PubMed ID: 18721898
    [Abstract] [Full Text] [Related]

  • 20. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.
    Exp Cell Res; 2009 Feb 01; 315(3):485-97. PubMed ID: 19071109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.